Celldex Therapeutics, Inc.  

(Public, NASDAQ:CLDX)   Watch this stock  
Find more results for CLDX
3.26
0.00 (0.00%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.21 - 3.31
52 week 2.85 - 8.75
Open 3.26
Vol / Avg. 1.17M/1.70M
Mkt cap 398.63M
P/E     -
Div/yield     -
EPS -1.30
Shares 122.28M
Beta 2.66
Inst. own 69%
Feb 23, 2017
Q4 2016 Celldex Therapeutics Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -1333.24% -2321.11%
Operating margin -1351.04% -2363.89%
EBITD margin - -2290.69%
Return on average assets -45.39% -43.44%
Return on average equity -52.55% -50.70%
Employees 196 -
CDP Score - -

Address

53 Frontage Rd Ste 220
HAMPTON, NJ 08827-4034
United States - Map
+1-908-2007500 (Phone)
+1-908-4541911 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Officers and directors

Larry Ellberger Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Anthony S. Marucci President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Avery W. Catlin CPA Chief Financial Officer, Senior Vice President, Secretary
Age: 66
Bio & Compensation  - Reuters
Tibor Keler Ph.D. Executive Vice President and Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Thomas Andrew Davis M.D. Executive Vice President and Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Elizabeth Crowley Senior Vice President, Chief Product Development Officer
Age: 45
Bio & Compensation  - Reuters
Theresa M. LaVallee Ph.D. Senior Vice President - Regulatory and Precision Medicine
Age: 50
Bio & Compensation  - Reuters
Ronald A. Pepin Ph.D. Senior Vice President and Chief Business Officer
Age: 59
Bio & Compensation  - Reuters
Richard Wright Ph.D. Senior Vice President, Chief Commercial Officer`
Bio & Compensation  - Reuters
Gerald McMahon Ph.D. Director
Age: 61
Bio & Compensation  - Reuters